King/Mylan Merger Will Provide Critical Mass To Develop Palatin's ED Agent
King will pay up to $250 mil. to in-license the Phase II agent PT-141 for female sexual dysfunction and erectile dysfunction. King says the melanocortin receptor agonist will provide better safety and efficacy compared to the currently marketed PDE-5 inhibitors.
More from Archive
More from Pink Sheet
European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.
Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.